Fingerprint
Dive into the research topics of 'KEYNOTE-641: A Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
KEYNOTE-641: A Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer
Julie N. Graff, Li Wen Liang, Jeri Kim, Arnulf Stenzl
Research output: Contribution to journal › Article › peer-review
16
Scopus
citations